Securities Fraud Class Action Over Charges Patients Did Not Envision
WASHINGTON, DC (August 24, 2017) — U.S. Market Advisors Law Group PLLC announces that a securities class action has been filed against Envision Healthcare Corporation (“Envision Healthcare” or the “Company”) (NYSE:EVJC). The class action is on behalf of investors who acquired Envision Healthcare securities between March 2, 2015 and July 21, 2017.
Investors with losses have until October 6, 2017 to ask the Court to appoint you as Lead Plaintiff for the class. The Lead Plaintiff is a representative for absent members of the class. Investors do not need to seek appointment as Lead Plaintiff to share in any class recovery in this action. If you are a class member and there is a recovery for the class, you can share in that recovery as an absent class member. You may retain counsel of your choice to represent you in this action. Contact USMA Law Group to discuss this action.
Envision Healthcare is a provider of healthcare services. The Company offers a range clinical solutions, including physician-led services, medical transportation, ambulatory services and post-acute services. The Company operates through three segments: physician services, medical transportation and ambulatory services. At all relevant times, EmCare Holdings, Inc. (“EmCare”) has been one of the Company’s primary operating subsidiaries.
Allegations Against Envision Healthcare
The Complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (i) EmCare routinely arranged for patients who sought treatment at in-network facilities to be treated by out-of-network physicians; (ii) EmCare accordingly billed these patients at higher rates than if the patients had received treatment from in-network physicians; (iii) the Company’s statements attributing EmCare’s Class Period growth to other factors were therefore false and/or misleading; (iv) Envision’s EmCare revenues were likely to be unsustainable after the foregoing conduct came to light; and (v) as a result of the foregoing, Envision’s public statements were materially false and misleading at all relevant times.
On July 24, 2017, The New York Times reported that hospitals associated with Envision’s subsidiary EmCare were disproportionately likely to engage in “surprise billing,” in which patients who sought treatment at in-network facilities were treated by out-of-network physicians and subsequently billed at higher rates.
On this news, Envision’s share price fell $2.33, or 3.72%, to close at $60.28 on July 24, 2017.
About USMA Law Group
U.S. Market Advisors Law Group PLLC is a national law firm based in Washington, D.C. The firm represents investors worldwide in U.S. securities class action lawsuits.
Contact
David P. Abel
(202) 274-0237
[email protected]